Return to Growth for This Dividend King

The analysts see this stock rising 10% at the low end of their target range. Unsubscribe

Good Morning, Abbott Laboratories' share price has trended lower for nearly two years, but that trend is over. The impact of the pandemic on sales and the post-pandemic letdown were cause enough for the market to sell, but not now; the market is oversold and overextended with normalization at hand. Normalization, a buzzword that can be applied to most industries today, means steadying sales of supplies offset by core business growth and, more importantly, a return to growth for this Dividend King in 2024. Click here to learn more about how Abbott Labs is offering a favorable entry point for investors. Take a look at these new offers and reports just for you: This Is the No. 1 NASDAQ Stock to Hold Even if the economy goes into a recession, this NASDAQ-listed company is going to continue to grow. If you plan to hold ANY stock and are looking for a solid addition to your portfolio, then you really need to see this one. It's considered a recession-proof company. From Darwin. **Click here to download the full report Protect Your Bank Account Before It's Too Late For months I've been warning about the federal government's terrifying new program to control every American's bank account. It gives them the power to monitor every single transaction … From Weiss Ratings. Stop right now and do these 3 things to protect yourself Why most folks lose in options trading Most people think of BUYING options when they talk about options.  It's how speculators leverage large sums of money hoping that a stock moves in the "right" direction over a certain period of time.  The problem is - they don't always pay off when you buy them.  In fact, a contributing writer at the Financial Post studied options extensively…  From DTI. Click here to see me place one of these trades LIVE on camera. "The Biggest Drug Ever" Is Coming UBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year. From Behind the Markets. Get the name of the stock here >>> Elon's master plan revealed? You heard it here first… "Project X." That's going to be Elon's next big move. And while most people have no idea what's coming… From MillPub. So click here now to get all the details, before it's too late. Important Update on U.S. Bank Accounts The mainstream news isn't breathing a word about it… … but the government is about to unleash a shocking change to bank accounts in the United States. It's going to rip away your privacy and control of your savings. From Investor Place Media. Click here to discover what the government's change is. Did You Get Your Free Bitcoin Yet? And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin. From Crypto Swap Profits. >> Register right here William Bushee MarketBeat

Thank you for subscribing to Insider Trades Daily, which covers the most recent insider buying and selling activity from Wall Street CEO's, CFO's, COO's and other insiders.   If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.   If you no longer wish to receive email from InsiderTrades.com, you can unsubscribe.   © 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Buy THIS stock before Taiwan is attacked